Trials / Completed
CompletedNCT01681576
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valsartan | Valsartan 320mg tablet once daily |
| DRUG | LCZ696 | LCZ696 400mg tablet once daily |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2012-09-10
- Last updated
- 2015-11-10
- Results posted
- 2015-10-09
Locations
15 sites across 5 countries: United States, Hong Kong, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01681576. Inclusion in this directory is not an endorsement.